Eli Lilly & Co. vs Royalty Pharma plc
LLY vs RPRX — side-by-side comparison from reported financials. LLY leads 8, RPRX leads 4 of 12 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Royalty Pharma plc
RPRX · Healthcare
$56.93+1.28%Solid
| Metric | LLY | RPRX |
|---|---|---|
| Price | $1 177.20 | $56.93 |
| Market cap | $1.05T | $25.4B |
| Revenue (TTM) | $79.7B | $2.54B |
| Revenue growth | +31.7% | +2.1% |
| Net margin | 33.5% | 32.1% |
| Free cash flow | $18.2B | $2.98B |
| Net cash (debt) | ($35.2B) | ($7.93B) |
| 1-year price return | +37.6% | +57.5% |
| P/E | 41.6 | 40.2 |
| P/E vs own history (cheap-side %) | 88% | 53% |
| Dividend yield | 0.52% | 1.22% |
| Return on equity | 93% | 12% |
| Altman Z-score | 7.10 | 2.32 |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 50,000 | 100 |
Full résumé-style profiles: LLY CV · RPRX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.